Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between ...
Sands Capital, an investment management company, released its “Sands Capital Select Growth Strategy” Q3 2025 investor letter.
Continuous Glucose Monitors, or CGMs, have been funded for Type 1 diabetes since last October, and there are calls to expand the funding to all diabetes pa ...
Labaton Keller Sucharow LLP ("Labaton") announces that, on November 25, 2025, it filed a securities class action lawsuit (the "Complaint") on behalf of its client Boston Retirement System ("Boston") ...
In a phase II trial, type 2 diabetes patients treated with amycretin -- an investigational long-acting GLP-1 and amylin receptor agonist -- had up to a 1.8% reduction in HbA1c and up to a 14.5% loss ...
The model, 34, and the comedian, 37, who are parents to daughter Elsie, two, became engaged when he popped the question in ...
American Diversified Holdings Corporation (OTCID: ADHC) announced today that GlucoGuard has completed the Level 2 App integration ...
At age 72, Nathan Harms still climbs ladders, hauls paint cans and balances on beams – tasks that demand precision, stamina ...
Dexcom has announced that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1.
The healthcare industry presents a wealth of opportunities for investors to generate notable portfolio returns over decades.
A medical technology firm specialising in continuous glucose monitoring systems for diabetes is set to relocate to Maxis Business Park in Bracknell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback